Giorgio Sesti - Concepedia

Author

Giorgio Sesti

Also Known As

Achiropita Pucci, Alessandro Nobili, Annalisa Natalicchio, Bruno Tassone, Francesco Andreozzi, G Sesti, G. Sesti, GIORGIO SESTI, Giorgio Sesti, Giorgio Sesti (258953)

584

Publications

22.5K

Citations

H-Index

180

Concepts

All Affiliations

Magna Graecia University Sapienza University of Rome University of Rome Tor Vergata Istituti di Ricovero e Cura a Carattere Scientifico University of Pisa

About

Giorgio Sesti is an author at Magna Graecia University specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	44	124	9.9K
2	Health Sciences	32	66	3K
3	Public Health	16	17	718
4	Natural Sciences	3	3	64
5	Engineering	2	2	36

Giorgio Sesti

278

Publications

17.9K

Citations

H-Index

Page 1

	Year	Citations
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, The Lancet Diabetes ManagementCardiovascular DiseaseDiabetesClinical TrialsType 2	2018	1.7K
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) John B. Buse, Julio Rosenstock, Giorgio Sesti, The Lancet Open-label TrialDiabetes ManagementMedicineDiabetesClinical Trials	2009	1.5K
Insulin-Dependent Activation of Endothelial Nitric Oxide Synthase Is Impaired by O-Linked Glycosylation Modification of Signaling Proteins in Human Coronary Endothelial Cells Massimo Federici, Rossella Menghini, Alessandro Mauriello, Circulation	2002	370
High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans Massimo Federici, Marta Letizia Hribal, Lucia Perego, Diabetes	2001	328
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial Olga Vaccaro, Maria Masulli, Antonio Nicolucci, The Lancet Diabetes & Endocrinology Diabetes ManagementCardiovascular DiseaseDiabetesPharmacologyCardiovascular Pharmacology	2017	285
Asymmetric Dimethylarginine, L-Arginine, and Endothelial Dysfunction in Essential Hypertension Francesco Perticone, Angela Sciacqua, Raffaele Maio, Journal of the American College of Cardiology HypertensionCardiovascular DiseaseMedicineAntihypertensive TherapyEndothelial Dysfunction	2005	267
Uric Acid and Endothelial Dysfunction in Essential Hypertension Carmine Zoccali, Raffaele Maio, Francesca Mallamaci, Journal of the American Society of Nephrology Serum CreatinineHypertensionUrologySerum Uric AcidRenal Function	2006	240
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes Michael A. Nauck, John R. Petrie, Giorgio Sesti, Diabetes Care	2015	219
Angiotensin II Impairs the Insulin Signaling Pathway Promoting Production of Nitric Oxide by Inducing Phosphorylation of Insulin Receptor Substrate-1 on Ser <sup>312</sup> and Ser <sup>616</sup> in Human Umbilical Vein Endothelial Cells Francesco Andreozzi, Emanuela Laratta, Angela Sciacqua, Circulation Research Nitric OxideInsulin ReceptorInsulin SignalingOxidative StressType 1	2004	205
Uric Acid Is Associated With Inflammatory Biomarkers and Induces Inflammation Via Activating the NF-κB Signaling Pathway in HepG2 Cells Rosangela Spiga, Maria Adelaide Marini, Elettra Mancuso, Arteriosclerosis Thrombosis and Vascular Biology	2017	205

Page 1